Azirkitug

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Protein
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Protein
www.ebi.ac.uk
Drug name
Azirkitug
www.ebi.ac.uk

  • azirkitug
  • Azirkitug
  • azirkitug [INN]
  • AZIRKITUG [USAN]
  • azirkitug inn
  • azirkitug usan
  • h gamma1 heavy chain humanized 1 450 vh homo sapiens ighv3 73 01 84 8 ighd ighj4 01 92 9 cdr imgt 8 10 11 26 33 51 60 99 109 1 120 homo sapiens ighg1 03v g1m3 g1m17 ng1m1 ch1 k120 ch3 e12 m14 ch1 r120 k 217 121 218 hinge 1 15 219 233 ch2 234 343 ch3 e12 359 m14 361 344 448 chs 449 450 121 450 223 214 disulfide with l kappa light chain humanized 1 214 v kappa homo sapiens igkv3 11 01 78 9 igkj2 01 100 cdr imgt 6 3 9 27 32 50 52 89 97 1 107 homo sapiens igkc 01 100 km3 a45 1 153 v101 191 108 214 dimer 229 229 232 232 bisdisulfide produced in a chinese hamster ovary cho cell line derived from the cell line cho dux b11 lacking the enzyme dihydrofolate reductase dhfr and co expressing the rmd enzyme gdp 6 deoxy dlyxo 4 hexulose reductase glycoform alfa
  • H-gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV3-73*01 (84.8%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT[8.10.11] (26-33.51-60.99-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with L-kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV3-11*01 (78.9%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in a Chinese hamster ovary (CHO) cell line, derived from the cell line CHO-DUX-B11, lacking the enzyme dihydrofolate reductase (DHFR), and co-expressing the RMD enzyme (GDP-6-deoxy-Dlyxo-4-hexulose reductase), glycoform alfa
  • immunoglobulin g1 anti human cc chemokine receptor ccr8 human rattus norvegicus monoclonal pr 1925514 γ1 chain disulfide with human rattus norvegicus monoclonal pr 1925514 κ chain dimer
  • immunoglobulin g1 kappa anti homo sapiens ccr8 c c motif chemokine receptor 8 ckr l1 cdw198 humanized monoclonal antibody
  • immunoglobulin G1-kappa, anti-[Homo sapiens CCR8 (C-C motif chemokine receptor 8, CKR-L1, CDw198)], humanized monoclonal antibody
  • Immunoglobulin G1, anti-(human CC chemokine receptor CCR8) (human-Rattus norvegicus monoclonal PR-1925514 γ1-chain), disulfide with human-Rattus norvegicus monoclonal PR-1925514 κ-chain, dimer
  • pr 1925514
  • PR-1925514
  • pr1925514
  • PR1925514

CAS registry numbers
  • 2837169-12-5
ChEMBL ID
CHEMBL6068092
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • R6HJ7X69JZ

First in class
No
Orphan designation
No

Investigated indications

  • Condition
    Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000616
    Subject identifier
    D009369

  • Condition identifier
    EFO_0000616
  • Condition identifier
    MONDO_0005070
  • Condition identifier
    MONDO_0005233
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0010150
    Highest recorded phase
    1

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Heavy chain
    Type
    Protein
    Sequence
    EVQLVESGGGLVQPGGSLKLSCAASGFIFSNAVMYWVRQASGKGLEWVARIKTKFNNYATYYADAVKGRFTISRDDSKNMVYLQMNSLKTEDTAVYYCTAGDRNKPFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  • Component
    Disulfide bridges
    Sequence
    22-98 $ 22''-98'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 147-203 $ 147''-203'' $ 223-214' $ 223''-214''' $ 229-229'' $ 232-232'' $ 264-324 $ 264''-324'' $ 370-428 $ 370''-428''
  • Component
    Light chain
    Type
    Protein
    Sequence
    ETVVTQSPATLSLSPGERATLSCRASTSVITLLHWFQQKPGQAPRLLIHGASNLESRVPARFSGSGSGTDFTLTISSLEPEDFATYFCQQSWNDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
  • Component
    Glycosylation sites (N)
    Sequence
    300 $ 300''

Related records

Trials (1)

In development for (1)